Giredestrant Cuts Disease Progression Risk by 44% in Phase III evERA Trial for Advanced Breast Cancer
- Giredestrant reduced the risk of disease progression or death by 44% compared with standard endocrine therapy plus everolimus in patients with ER-positive advanced breast cancer, according to phase...
- The 44% risk reduction comes from the intention-to-treat population in the large, randomized trial.
- Everolimus combined with an aromatase inhibitor has served as a standard treatment option since earning FDA approval in 2012.
Giredestrant reduced the risk of disease progression or death by 44% compared with standard endocrine therapy plus everolimus in patients with ER-positive advanced breast cancer, according to phase III evERA trial results published October 1 in The New England Journal of Medicine.
Phase III evERA Trial Results and Progression-Free Survival
The 44% risk reduction comes from the intention-to-treat population in the large, randomized trial. The data mark the clearest evidence to date that an oral selective estrogen receptor degrader (SERD) paired with an mTOR inhibitor can outperform the current backbone regimen rather than just match it. Roche’s earlier phase II coopERA study had already demonstrated that giredestrant beat standard of care on anti-proliferative activity in early-stage disease, making a phase III signal anticipated. According to trial analysis, a 44% risk reduction in a large, randomized trial provides a strong dataset for regulatory review compared to a biomarker endpoint in a neoadjuvant setting. Publication in The New England Journal of Medicine also places the full dataset before regulators and payers simultaneously.
Clinical Context and Treatment Standards
Everolimus combined with an aromatase inhibitor has served as a standard treatment option since earning FDA approval in 2012. For patients who experience disease progression on prior hormonal therapy, adding the injectable SERD fulvestrant to that backbone has been the conventional incremental move. While giredestrant is oral, eliminating the intramuscular injection burden associated with older therapies, investigators emphasize that the primary clinical argument rests on the progression-free survival separation rather than the route of administration alone.
Regulatory Review and Overall Survival Readouts
The practical question facing clinicians now is whether overall survival data will follow the progression-free survival curve. While regulatory bodies increasingly accept progression-free survival as a primary endpoint in ER-positive metastatic breast cancer, payer committees in several markets require overall survival data or a patient-reported outcomes signal before committing to reimbursement pricing that reflects a step-change over existing therapy. The upcoming overall survival readout from the evERA trial will determine whether giredestrant secures a label position ahead of the current standard rather than alongside it.